These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8089365)

  • 21. Nicotinamide as a repair inhibitor in vivo: studies using single and fractionated X-ray doses in mouse skin and kidneys.
    Rojas A; Denekamp J; Johns H; Kjellen E; Tsang R; Nilsson P; Stratford MR; Dennis MF; Joiner MC
    Radiat Res; 1996 Apr; 145(4):419-31. PubMed ID: 8600502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of cell survival, DNA double strand breaks, and DNA synthesis during concurrent camptothecin and X-radiation treatments.
    Ng CE; Mazaheri K; Payant C; Raaphorst GP
    Int J Cancer; 2001 Oct; 96(5):277-85. PubMed ID: 11582580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
    Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
    J Surg Oncol; 1993 Jun; 53(2):97-103. PubMed ID: 8388965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Camptothecin post-treatments inhibit the biochemical events linked to the tumor-promoting component of carcinogenesis in mouse epidermis in vivo.
    Gao XM; Perchellet EM; Davis AW; Newell SW; Chen G; Hua DH; Perchellet JP
    Int J Cancer; 1996 May; 66(4):496-505. PubMed ID: 8635865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA topoisomerase I changes the mode of interaction between camptothecin drugs and DNA as probed by UV-resonance Raman spectroscopy.
    Feofanov AV; Baranov AV; Fleury F; Riou JF; Nabiev IR; Manfait M
    FEBS Lett; 1996 Nov; 396(2-3):289-92. PubMed ID: 8915005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
    Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
    Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of adriamycin and actinomycin D on radiation-induced skin reactions in mouse feet.
    Redpath JL; Colman M
    Int J Radiat Oncol Biol Phys; 1979 Apr; 5(4):483-6. PubMed ID: 457493
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.
    Walsh MD; Hanna SK; Sen J; Rawal S; Cabral CB; Yurkovetskiy AV; Fram RJ; Lowinger TB; Zamboni WC
    Clin Cancer Res; 2012 May; 18(9):2591-602. PubMed ID: 22392910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA topoisomerase I poisons.
    Takimoto CH; Kieffer LV; Kieffer ME; Arbuck SG; Wright J
    Cancer Chemother Biol Response Modif; 1999; 18():81-124. PubMed ID: 10800479
    [No Abstract]   [Full Text] [Related]  

  • 30. The therapeutic advantage of combined X-rays and melphalan.
    Joiner MC; Bremner JC; Denekamp J
    Int J Radiat Oncol Biol Phys; 1984 Mar; 10(3):385-92. PubMed ID: 6706732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined effects of hyperthermia and CPT-11 on DNA strand breaks in mouse mammary carcinoma FM3A cells.
    Kondo T; Ueda K; Kano E
    Anticancer Res; 1995; 15(1):83-6. PubMed ID: 7733646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early and late effects of cisplatin and radiation at acute and low dose rates on the mouse skin and soft tissues of the leg.
    Fu KK; Lam KN
    Int J Radiat Oncol Biol Phys; 1991 Feb; 20(2):327-32. PubMed ID: 1991697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.
    Kim R; Hirabayashi N; Nishiyama M; Jinushi K; Toge T; Okada K
    Int J Cancer; 1992 Mar; 50(5):760-6. PubMed ID: 1312063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.
    Akagi T; Ushinohama K; Kage Y; Ishizaki T; Makinosumi T; Yamauchi A; Taguchi Y; Inoue K; Yukawa E; Higuchi S; Ohdo S
    Life Sci; 2003 Jan; 72(10):1183-97. PubMed ID: 12505548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationship of acute to late skin injury in 2 and 5 fraction/week gamma-ray therapy.
    Withers HR; Thames HD; Flow BL; Mason KA; Hussey DH
    Int J Radiat Oncol Biol Phys; 1978; 4(7-8):595-601. PubMed ID: 711531
    [No Abstract]   [Full Text] [Related]  

  • 36. Modification of the response of mouse skin to x-irradiation by bleomycin treatment.
    Leith JT; Lewinsky BS; Schilling WA
    Radiat Res; 1975 Jan; 61(1):100-9. PubMed ID: 46119
    [No Abstract]   [Full Text] [Related]  

  • 37. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
    Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
    Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo.
    Du H; Huang Y; Hou X; Quan X; Jiang J; Wei X; Liu Y; Li H; Wang P; Zhan M; Ai X; Lu L; Yuan S; Sun L
    Eur J Pharm Sci; 2018 Oct; 123():546-559. PubMed ID: 30118848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
    Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
    Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
    Utsugi T; Aoyagi K; Asao T; Okazaki S; Aoyagi Y; Sano M; Wierzba K; Yamada Y
    Jpn J Cancer Res; 1997 Oct; 88(10):992-1002. PubMed ID: 9414662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.